MedTrace Logo

PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC

NCT03442569 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2025-07-01

Study results available
· View outcomes & findings →

Summary

To investigate the combination of nivolumab and ipilimumab with panitumumab in subjects with unresectable, refractory, KRAS/NRAS/BRAF wild-type, microsatellite stable (MSS) metastatic colorectal cancer.

Conditions

Interventions

DRUG

Panitumumab

6 mg/kg via IV every 2 weeks in combination with nivolumab and ipilimumab

DRUG

Nivolumab

240 mg via IV every 2 weeks in combination with panitumumab and ipilimumab

DRUG

Ipilimumab

1 mg/kg via IV every 6 weeks in combination with nivolumab and panitumumab

Sponsors & Collaborators

  • Amgen

    collaborator INDUSTRY

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Hanna K Sanoff, MD · University of North Carolina, Chapel Hill

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-09
Primary Completion
2020-09-21
Completion
2024-12-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03442569 on ClinicalTrials.gov